scholarly journals Prostaglandin Reductase 1 as a Potential Therapeutic Target for Cancer Therapy

2021 ◽  
Vol 12 ◽  
Author(s):  
Xing Wang ◽  
Guobing Yin ◽  
Wei Zhang ◽  
Kunlin Song ◽  
Longbin Zhang ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Cancer Therapeutics ◽  
Tumor Metabolism ◽  
Leukotriene B4 ◽  
Arachidonic Acid Metabolism ◽  
Future Directions ◽  
Novel Target ◽  
Potential Inhibitors ◽  
Rate Limiting ◽  
Made In

Altered tumor metabolism is a hallmark of cancer and targeting tumor metabolism has been considered as an attractive strategy for cancer therapy. Prostaglandin Reductase 1 (PTGR1) is a rate-limiting enzyme involved in the arachidonic acid metabolism pathway and mainly responsible for the deactivation of some eicosanoids, including prostaglandins and leukotriene B4. A growing evidence suggested that PTGR1 plays a significant role in cancer and has emerged as a novel target for cancer therapeutics. In this review, we summarize the progress made in recent years toward the understanding of PTGR1 function and structure, highlight the roles of PTGR1 in cancer, and describe potential inhibitors of PTGR1. Finally, we provide some thoughts on future directions that might facilitate the PTGR1 research and therapeutics development.

scholarly journals DNA damaging agent-based antibody-drug conjugates for cancer therapy

2018 ◽  
Vol 1 (2) ◽  
pp. 43-53 ◽  
Author(s):  
Ying Fu ◽  
Mitchell Ho
Keyword(s):  
Cancer Therapy ◽  
Cancer Therapeutics ◽  
Future Directions ◽  
Agent Based ◽  
Antibody Drug Conjugates ◽  
Microtubule Inhibitors ◽  
Drug Conjugates ◽  
Dna Damaging Agents ◽  
Further Development ◽  
Antibody Drug

ABSTRACT Currently, four antibody-drug conjugates (ADCs) are approved by the Food and Drug Administration or the European Medicine Agency to treat cancer patients. More than 60 ADCs are in clinical development for cancer therapy. More than 60% of ADCs in clinical trials employ microtubule inhibitors as their payloads. A better understanding of payloads other than microtubule inhibitors, especially DNA-damaging agents, is important for further development of ADCs. In this review, we highlight an emerging trend of using DNA-damaging agents as payloads for ADCs. This review summarizes recent advances in our understanding gained from ongoing clinical studies; it will help to define the utility of DNA-damaging payloads for ADCs as cancer therapeutics. Future directions of the development of ADCs are also discussed, focusing on targeting drug resistance and combination treatment with immunotherapy.

Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players

2020 ◽  
Vol 26 ◽  
Author(s):  
Emir Muzurović ◽  
Zoja Stanković ◽  
Zlata Kovačević ◽  
Benida Šahmanović Škrijelj ◽  
Dimitri P Mikhailidis
Keyword(s):  
Diabetes Mellitus ◽  
Inflammatory Markers ◽  
High Specificity ◽  
Future Directions ◽  
Effective Strategies ◽  
Advantages And Disadvantages ◽  
Type 2 Dm ◽  
Increased Risk ◽  
Made In

: Diabetes mellitus (DM) is a chronic and complex metabolic disorder, and also an important cause of cardiovascular (CV) diseases (CVDs). Subclinical inflammation, observed in patients with type 2 DM (T2DM), cannot be considered the sole or primary cause of T2DM in the absence of classical risk factors, but it represents an important mechanism that serves as a bridge between primary causes of T2DM and its manifestation. Progress has been made in the identification of effective strategies to prevent or delay the onset of T2DM. It is important to identify those at increased risk for DM by using specific biomarkers. Inflammatory markers correlate with insulin resistance (IR) and glycoregulation in patients with DM. Also, several inflammatory markers have been shown to be useful in assessing the risk of developing DM and its complications. However, the intertwining of pathophysiological processes and the not-quite-specificity of inflammatory markers for certain clinical entities limits their practical use. In this review we consider the advantages and disadvantages of various inflammatory biomarkers of DM that have been investigated to date as well as possible future directions. Key features of such biomarkers should be high specificity, non-invasiveness and cost-effectiveness.

scholarly journals Targeting DNA Repair and Chromatin Crosstalk in Cancer Therapy

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 381
Author(s):  
Danielle P. Johnson ◽  
Mahesh B. Chandrasekharan ◽  
Marie Dutreix ◽  
Srividya Bhaskara
Keyword(s):  
Dna Repair ◽  
Cancer Therapy ◽  
Therapeutic Intervention ◽  
Synthetic Lethality ◽  
Checkpoint Proteins ◽  
Cellular Processes ◽  
Repair Pathways ◽  
Made In

Aberrant DNA repair pathways that underlie developmental diseases and cancers are potential targets for therapeutic intervention. Targeting DNA repair signal effectors, modulators and checkpoint proteins, and utilizing the synthetic lethality phenomena has led to seminal discoveries. Efforts to efficiently translate the basic findings to the clinic are currently underway. Chromatin modulation is an integral part of DNA repair cascades and an emerging field of investigation. Here, we discuss some of the key advancements made in DNA repair-based therapeutics and what is known regarding crosstalk between chromatin and repair pathways during various cellular processes, with an emphasis on cancer.

scholarly journals Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy

Biomolecules ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 395
Author(s):  
Aikaterini Berdiaki ◽  
Monica Neagu ◽  
Eirini-Maria Giatagana ◽  
Andrey Kuskov ◽  
Aristidis M. Tsatsakis ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Targeted Delivery ◽  
Academic Research ◽  
Cancer Therapeutics ◽  
Disease Evolution ◽  
Structure Changes ◽  
Recent Developments ◽  
Distribution Composition ◽  
Membrane Components ◽  
Cancer Tissues

The tumor microenvironment (TME) is composed of cancerous, non-cancerous, stromal, and immune cells that are surrounded by the components of the extracellular matrix (ECM). Glycosaminoglycans (GAGs), natural biomacromolecules, essential ECM, and cell membrane components are extensively altered in cancer tissues. During disease progression, the GAG fine structure changes in a manner associated with disease evolution. Thus, changes in the GAG sulfation pattern are immediately correlated to malignant transformation. Their molecular weight, distribution, composition, and fine modifications, including sulfation, exhibit distinct alterations during cancer development. GAGs and GAG-based molecules, due to their unique properties, are suggested as promising effectors for anticancer therapy. Considering their participation in tumorigenesis, their utilization in drug development has been the focus of both industry and academic research efforts. These efforts have been developing in two main directions; (i) utilizing GAGs as targets of therapeutic strategies and (ii) employing GAGs specificity and excellent physicochemical properties for targeted delivery of cancer therapeutics. This review will comprehensively discuss recent developments and the broad potential of GAG utilization for cancer therapy.

scholarly journals Senolytics for Cancer Therapy: Is All that Glitters Really Gold?

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 723
Author(s):  
Valerie J. Carpenter ◽  
Tareq Saleh ◽  
David A. Gewirtz
Keyword(s):  
Cancer Therapy ◽  
Tumor Cell ◽  
Cancer Therapies ◽  
Cell Models ◽  
Future Directions ◽  
Targeted Cancer Therapies

Senolytics represent a group of mechanistically diverse drugs that can eliminate senescent cells, both in tumors and in several aging-related pathologies. Consequently, senolytic use has been proposed as a potential adjuvant approach to improve the response to senescence-inducing conventional and targeted cancer therapies. Despite the unequivocal promise of senolytics, issues of universality, selectivity, resistance, and toxicity remain to be further clarified. In this review, we attempt to summarize and analyze the current preclinical literature involving the use of senolytics in senescent tumor cell models, and to propose tenable solutions and future directions to improve the understanding and use of this novel class of drugs.

Tumor Metabolism: Focused on Tumor Glycolysis, Progress, and Prospects in Cancer Therapy

2021 ◽  
pp. 1-33
Author(s):  
Atul Kumar ◽  
Mamta Singh ◽  
Dolly Sharma ◽  
Vinit Kumar ◽  
Reshma Rani
Keyword(s):  
Cancer Therapy ◽  
Tumor Metabolism ◽  
Tumor Glycolysis

Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy

2018 ◽  
Vol 52 (6) ◽  
pp. 718-723 ◽  
Author(s):  
Shoyo Shibata ◽  
Maiko Matsushita ◽  
Yoshimasa Saito ◽  
Takeshi Suzuki
Keyword(s):  
Cancer Therapy ◽  
Anticancer Drug ◽  
Drug Prescription ◽  
Future Directions ◽  
Prescription Patterns

Philippine Archaeology: Status and Prospects

1987 ◽  
Vol 18 (2) ◽  
pp. 235-249 ◽  
Author(s):  
Karl L. Hutterer
Keyword(s):  
Present Form ◽  
Historical Events ◽  
Research Practices ◽  
Future Directions ◽  
Historical Perspectives ◽  
Present Essay ◽  
History Of ◽  
Future Potential ◽  
Made In

The purpose of the present essay is not to present a history of Philippine archaeology; several preliminary attempts have been made in this regard which may be consulted. Rather, the aim of this paper is to pause for a moment and look across the landscape of Philippine archaeology to assess what has been accomplished to date, to ponder strength and weaknesses of the field at this time, and to consider future directions. Nevertheless, the shape of any landscape is the result of historical events and processes that need to be taken into account if we want to understand its present form and assess its future potential and development. Thus, it will be necessary to include in the following thoughts historical perspectives which will help to explain how and why certain concepts, methods and research practices arose in the context of Philippine archaeology and came to determine our picture of Philippine prehistory.

scholarly journals Erythroblast Enucleation

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Ganesan Keerthivasan ◽  
Amittha Wickrema ◽  
John D. Crispino
Keyword(s):  
Red Blood Cells ◽  
Blood Cells ◽  
Ex Vivo ◽  
Critical Rate ◽  
Future Directions ◽  
Mammalian Erythrocyte ◽  
Rate Limiting

Even though the production of orthochromatic erythroblasts can be scaled up to fulfill clinical requirements, enucleation remains one of the critical rate-limiting steps in the production of transfusable red blood cells. Mammalian erythrocytes extrude their nucleus prior to entering circulation, likely to impart flexibility and improve the ability to traverse through capillaries that are half the size of erythrocytes. Recently, there have been many advances in our understanding of the mechanisms underlying mammalian erythrocyte enucleation. This review summarizes these advances, discusses the possible future directions in the field, and evaluates the prospects for improved ex vivo production of red blood cells.

Sign in / Sign up

Export Citation Format

Share Document